RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Author(s) -
Patrick A. Oberholzer,
Damien Kee,
Piotr Dziunycz,
Antje Sucker,
Nyam Kamsu-Kom,
Robert T. Jones,
Christine Roden,
Clinton J. Chalk,
Kristin Ardlie,
Emanuele Palescandolo,
Adriano Piris,
Laura E. MacConaill,
Caroline Robert,
Günther F.L. Hofbauer,
Grant A. McArthur,
Dirk Schadendorf,
Levi A. Garraway
Publication year - 2011
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2011.36.7680
Subject(s) - hras , medicine , kras , cancer research , cdkn2a , neuroblastoma ras viral oncogene homolog , immunosuppression , mutation , cancer , vemurafenib , melanoma , gene , colorectal cancer , biology , metastatic melanoma , biochemistry
RAF inhibitors are effective against melanomas with BRAF V600E mutations but may induce keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cSCCs). The potential of these agents to promote secondary malignancies is concerning. We analyzed cSCC and KA lesions for genetic mutations in an attempt to identify an underlying mechanism for their formation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom